Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; A randomized, double-blind, placebo-controlled trial

Journal of Obstetrics and Gynaecology Research

Volumn 34, Issue 1, 2008, Pages 34-39

  Sameshima, Hiroshi ^a   Kodama, Yuki ^a   Ikenoue, Tsuyomu ^a   Kajiwara, Yayoi ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b CSL Behring KK   (Japan)

Author keywords

Antithrombin; Biophysical profile score; Fetal heart rate monitoring; Fetal weight gain; Pre eclampsia

Indexed keywords

ALBUMIN; ANTITHROMBIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECLAMPSIA; FEMALE; FETUS; FETUS ELECTROCARDIOGRAPHY; FETUS HEART RATE; FETUS MONITORING; FETUS WEIGHT; FOLLOW UP; GESTATION PERIOD; GESTATIONAL AGE; HELLP SYNDROME; HEMOLYSIS; HUMAN; INCIDENCE; INFANT MORTALITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREECLAMPSIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; WEIGHT GAIN;

ADULT; ANTICOAGULANTS; ANTITHROMBINS; BIRTH WEIGHT; DOUBLE-BLIND METHOD; FEMALE; FETUS; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INJECTIONS, INTRAVENOUS; JAPAN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38449108089     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2007.00677.x     Document Type: Article

References (12)

1. Maki M, Kobayashi T, Terao T et al. Antithrombin therapy for severe pre-eclampsia: result of a double-blind, randomized, placebo-controlled trial. Thromb Haemost 2000 84 : 583 590.
2. Terao T, Kobayashi T, Imai N, Oda H, Karasawa T. Pathological state of the coagulatory and fibrinolytic system in pre-eclampsia and the possibility of its treatment with AT III concentrate. Asia-Oceania J Obstet Gynecol 1989 15 : 25 32.
3. Terao T, Maki M, Ikenoue T et al. The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy. Gynecol Obstet Invest 1991 31 : 74 85.
4. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001 86 : 298 307.
5. Paternoster DM, Fusco DD, Tambuscio B. Treatment with antithrombin III (AT III) concentrate in pre-eclampsia. Int J Obstet Gynecol 2000 31 : 175 176.
6. Weenink GH, ten Cate JW, Treffers PE, Smorenberg-Schoorl ME. Blood coagulation in pregnancy induced hypertension. Scand J Clin Lab Invest Suppl 1985 178 : 99 105.
7. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991 64 : 1057 1068.
8. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin (III) binding properties. J Biol Chem 1992 267 : 20435 20443.
9. Jokimaa VLS, Kuraji HP, Ekholm EMK, Inki PLK, Anttila L. Placental expression of syndecan 1 is diminished in pre-eclampsia. Am J Obstet Gynecol 2000 183 : 1495 1498.
10. Filla MS, Dam P, Rapraeger AC. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol 1998 174 : 310 321.
11. Yamaguchi M, Mibe M, Ikenoue T. Role of syndecan 1 on placental thromboxane production. In : Cabero L, Carrera JM (eds). Perinatology 2001. 5th World Congress of Perinatal Medicine. Madrid : Monduzzi Editore, 2001 1081 1083.
12. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989 163 : 1404 1411.